After Clearing the FDA Approval Hurdle, Bay Area Therapies Hit the Market -- or Not
The good news: Bay Area companies racked up at least 15 drug approvals this year, crushing the previous four years combined. The bad news? Now they must convince doctors to prescribe those drugs and insurers to pay for them to recoup drug-development investments totaling in the billions of dollars.